Fox Chase Cancer Center study links oxygen levels and angiogenesis in prostate cancer

October 22, 2000

PHILADELPHIA (October 23, 2000) -- A new study demonstrates a significant association between a lack of oxygen in prostate cancer cells and the increased expression of the angiogenesis marker, endothelial growth factor or VEGF. The Fox Chase Cancer Center study was presented at the American Society for Therapeutic Radiology and Oncology Annual Meeting in Boston, Mass. on October 23 at 10:45 a.m.

The lack of oxygen, called hypoxia, in tumor cells has been shown to correlate, not only with poor response to radiotherapy, but also to tumor aggressiveness.

"Prior studies have shown that cancer cells adapt to hypoxia by secreting angiogenic growth factors, such as vascular VEGF," explained James V. Tricoli, Ph.D., an associate member in the medical sciences division of Fox Chase and an author of the study. "The purpose of this study was to determine if increasing levels of hypoxia are associated with increased production of VEGF in prostate cancer."

In the study, the oxygen levels in prostate tumor cells were measured in 13 men undergoing radical prostatectomy. Each tumor comprised approximately 100 separate oxygen readings. Tumor tissue from the prostatectomy specimens was then analyzed to measure the level of VEGF. Using a published methodology, two independent observers (blinded to the oxygen data) scored the percent of cells staining positive for VEGF and the staining intensity. The significance of associations between oxygen levels and VEGF staining was determined by Pearson correlation.

"The blinded comparison of oxygen levels and VEGF staining intensity reveals a clear link between increasing hypoxia and VEGF," said Benjamin Movsas, M.D., director of clinical radiotherapy research at Fox Chase. "These findings support examining anti-angiogenic strategies in treating prostate cancer."
-end-
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at: www.fccc.edu.

Abstract #45 Increasing Hypoxia Correlates with Increased Expression of the Angiogenesis Marker VEGF in Human Prostate Carcinoma is to be presented Oct. 23, 2000 at 10:45 a.m.

Fox Chase Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.